Domschke W, Lux G, Domschke S, Strunz U, Bloom S R, Wünsch E
Department of Medicine, University of Erlangen-Nuremberg, Germany.
Gastroenterology. 1978 Jul;75(1):9-12.
Vasoactive intestinal peptide (VIP) administered as an intravenous infusion at different doses (0.8, 1.6, and 3.2 micrograms per kg per hr, respectively) inhibited dose-dependently the response of the lower esophageal sphincter to an intravenous injection of pentagastrin (0.6 microgram per kg) in 4 healthy volunteers. Inhibition ranged from about 20% (not significant) with the low dose to about 55% (P less than 0.05) with the high dose. On the other hand, the VIP doses employed did not substantially decrease basal lower esophageal sphincter pressure. Calculated on the basis of plasma levels of the respective peptides, the inhibitory effect of VIP was about one-third of that of secretin. Even at the smallest dose of VIP, plasma levels of radioimmunoassayable VIP (20 to 100 pmoles per liter) markedly exceeded those encountered normally (1 to 19 pmoles per liter). So, the data presented do not support the suggestion that normally circulating VIP essentially contributes to the physiological regulation of the lower esophageal sphincter pressure; they do not exclude, however, such a role for locally released VIP.
以不同剂量（分别为每千克每小时0.8、1.6和3.2微克）静脉输注血管活性肠肽（VIP），可剂量依赖性地抑制4名健康志愿者的下食管括约肌对静脉注射五肽胃泌素（每千克0.6微克）的反应。抑制率从低剂量时的约20%（无显著性差异）到高剂量时的约55%（P<0.05）。另一方面，所用的VIP剂量并未显著降低下食管括约肌的基础压力。根据相应肽的血浆水平计算，VIP的抑制作用约为促胰液素的三分之一。即使在最小剂量的VIP时，放射免疫法可检测到的VIP血浆水平（每升20至100皮摩尔）也明显超过正常水平（每升1至19皮摩尔）。因此，所呈现的数据不支持正常循环的VIP对下食管括约肌压力进行生理调节的观点；然而，它们并不排除局部释放的VIP具有这样的作用。
